Ersin İbişoğlu1, Sinem Çakal2, Beytullah Çakal3, H Murat Güneş3, Bedrettin Boyraz4, Bilal Boztosun3. 1. Department of Cardiology, Başakşehir Çam and Sakura City Hospital; İstanbul-Turkey. 2. Department of Cardiology, İstanbul Haseki Training and Research Hospital; İstanbul-Turkey. 3. Department of Cardiology, İstanbul Medipol University; İstanbul-Turkey. 4. Department of Cardiology, Tatvan State Hospital; Bitlis-Turkey.
Abstract
OBJECTIVE: The data on using novolimus-eluting DESolve bioresorbable scaffolds (BVS) for long-segment coronary artery lesions remains insufficient. In this study, our main objective was to assess the long-term effects of the overlapping applications of both DESolve-DESolve and the drug-eluting stent (DES)-DESolve. METHODS: A single-centered study of 103 patients scheduled for DESolve placement for long-segment lesions (>28 mm) was conducted (October 2013 to November 2016). A DESolve-DESolve overlap was used on 43 patients and a DES-DESolve overlap on 60 patients. Acute procedural success and major adverse cardiac events (MACE) (stent thrombosis, targeted vessel revascularization, targeted lesion revascularization, and cardiac death) were evaluated. The patients were followed up for 48 months. RESULTS: Revascularization was performed on 4 (6.7%) patients in the DES-DESolve group and 5 (11.6%) patients in the DESolve-DESolve group for target lesion revascularization. Among the study population, 10 (9.7%) patients had MACE, including 5 (8.3%) patients in the DES-DESolve group and 5 (11.6%) patients in the DESolve-DESolve group. CONCLUSION: The positive results of our study concerning the use of DESolve for the treatment of long coronary lesions demonstrate that BVS will emerge with new platforms and become non-inferior to the DES.
OBJECTIVE: The data on using novolimus-eluting DESolve bioresorbable scaffolds (BVS) for long-segment coronary artery lesions remains insufficient. In this study, our main objective was to assess the long-term effects of the overlapping applications of both DESolve-DESolve and the drug-eluting stent (DES)-DESolve. METHODS: A single-centered study of 103 patients scheduled for DESolve placement for long-segment lesions (>28 mm) was conducted (October 2013 to November 2016). A DESolve-DESolve overlap was used on 43 patients and a DES-DESolve overlap on 60 patients. Acute procedural success and major adverse cardiac events (MACE) (stent thrombosis, targeted vessel revascularization, targeted lesion revascularization, and cardiac death) were evaluated. The patients were followed up for 48 months. RESULTS: Revascularization was performed on 4 (6.7%) patients in the DES-DESolve group and 5 (11.6%) patients in the DESolve-DESolve group for target lesion revascularization. Among the study population, 10 (9.7%) patients had MACE, including 5 (8.3%) patients in the DES-DESolve group and 5 (11.6%) patients in the DESolve-DESolve group. CONCLUSION: The positive results of our study concerning the use of DESolve for the treatment of long coronary lesions demonstrate that BVS will emerge with new platforms and become non-inferior to the DES.
Authors: Vasim Farooq; Yoshinobu Onuma; Maria Radu; Takayuki Okamura; Josep Gomez-Lara; Salvatore Brugaletta; Bill D Gogas; Robert-Jan van Geuns; Evelyn Regar; Carl Schultz; Stephan Windecker; Thierry Lefèvre; B R Guus Brueren; Jennifer Powers; Laura L Perkins; Richard J Rapoza; Renu Virmani; Hector M García-García; Patrick W Serruys Journal: EuroIntervention Date: 2011-07 Impact factor: 6.534
Authors: Gabriel T R Pereira; Alessio La Manna; Yasuhiro Ichibori; Armando Vergara-Martel; Bruno Ramos Nascimento; Abdul Jawwad Samdani; Davide Capodanno; Guido D'Agosta; Giacomo Gravina; Giuseppe Venuti; Corrado Tamburino; Guilherme F Attizzani Journal: Int J Cardiovasc Imaging Date: 2019-06-07 Impact factor: 2.357
Authors: Stefan Verheye; Ricardo A Costa; Joachim Schofer; John A Ormiston; Michael Maeng; Dariusz Dudek; Carsten Skurk; Roberto V Botelho; J Ribamar Costa; Daniel Chamié; Andrea S Abizaid; Eric Boersma; Alexandre A Abizaid Journal: EuroIntervention Date: 2019-10-20 Impact factor: 6.534
Authors: Alexandre Abizaid; Ricardo A Costa; Joachim Schofer; John Ormiston; Michael Maeng; Bernhard Witzenbichler; Roberto V Botelho; J Ribamar Costa; Daniel Chamié; Andrea S Abizaid; Juliana P Castro; Lynn Morrison; Sara Toyloy; Vinayak Bhat; John Yan; Stefan Verheye Journal: JACC Cardiovasc Interv Date: 2016-03-28 Impact factor: 11.195
Authors: Vasim Farooq; Pascal Vranckx; Laura Mauri; Donald E Cutlip; Jorge Belardi; Sigmund Silber; Petr Widimsky; Martin Leon; Stephan Windecker; Ian Meredith; Manuela Negoita; Frank van Leeuwen; Franz-Joseph Neumann; Alan C Yeung; Hector M Garcia-Garcia; Patrick W Serruys Journal: Heart Date: 2013-03-06 Impact factor: 5.994
Authors: Stefan Verheye; John A Ormiston; James Stewart; Mark Webster; Elias Sanidas; Ricardo Costa; J Ribamar Costa; Daniel Chamie; Andrea S Abizaid; Ibraim Pinto; Lynn Morrison; Sara Toyloy; Vinayak Bhat; John Yan; Alexandre Abizaid Journal: JACC Cardiovasc Interv Date: 2013-10-16 Impact factor: 11.195